Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
Tuesday, October 04, 2016
VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales.
VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra.
VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million.
Source : reuters.com
